Cinedigm (CIDM) Competitors

$1.02
-0.04 (-3.77%)
(As of 05/17/2024 ET)

CIDM vs. BTX, ALFIW, and NLOK

Should you be buying Cinedigm stock or one of its competitors? The main competitors of Cinedigm include Brooklyn ImmunoTherapeutics (BTX), Alfi (ALFIW), and NortonLifeLock (NLOK). These companies are all part of the "information" sector.

Cinedigm vs.

Cinedigm (NASDAQ:CIDM) and Brooklyn ImmunoTherapeutics (NYSE:BTX) are both small-cap information companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, community ranking, earnings, valuation and media sentiment.

Cinedigm has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500. Comparatively, Brooklyn ImmunoTherapeutics has a beta of 4.61, indicating that its stock price is 361% more volatile than the S&P 500.

8.0% of Cinedigm shares are held by institutional investors. Comparatively, 26.0% of Brooklyn ImmunoTherapeutics shares are held by institutional investors. 16.4% of Cinedigm shares are held by insiders. Comparatively, 20.5% of Brooklyn ImmunoTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cinedigm and Brooklyn ImmunoTherapeutics both received 0 outperform votes by MarketBeat users.

CompanyUnderperformOutperform
CinedigmOutperform Votes
No Votes
Underperform Votes
34
100.00%
Brooklyn ImmunoTherapeuticsOutperform Votes
No Votes
Underperform Votes
72
100.00%

Brooklyn ImmunoTherapeutics has lower revenue, but higher earnings than Cinedigm. Cinedigm is trading at a lower price-to-earnings ratio than Brooklyn ImmunoTherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cinedigm$72.33M2.64-$9.35M-$0.05-20.40
Brooklyn ImmunoTherapeuticsN/AN/AN/A-$2.27-0.88

In the previous week, Cinedigm and Cinedigm both had 1 articles in the media. Cinedigm's average media sentiment score of 0.00 equaled Brooklyn ImmunoTherapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cinedigm
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Brooklyn ImmunoTherapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cinedigm
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Brooklyn ImmunoTherapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Company Net Margins Return on Equity Return on Assets
CinedigmN/A N/A N/A
Brooklyn ImmunoTherapeutics N/A N/A N/A

Summary

Brooklyn ImmunoTherapeutics beats Cinedigm on 4 of the 6 factors compared between the two stocks.

Get Cinedigm News Delivered to You Automatically

Sign up to receive the latest news and ratings for CIDM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CIDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CIDM vs. The Competition

MetricCinedigmMotion Picture and Video Production IndustryInformation SectorNASDAQ Exchange
Market Cap$190.65M$190.65M$3.67B$7.96B
Dividend YieldN/AN/A3.69%3.91%
P/E Ratio-20.40N/A7.3517.70
Price / Sales2.642.643.8675.92
Price / CashN/AN/AN/A31.88
Price / BookN/AN/AN/A4.76
Net Income-$9.35MN/AN/A$217.17M
7 Day Performance22.17%22.17%3.48%2.90%
1 Month Performance-10.53%-10.53%0.71%6.66%
1 Year PerformanceN/AN/A0.97%9.89%

Cinedigm Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BTX
Brooklyn ImmunoTherapeutics
0 of 5 stars
$2.02
-6.5%
N/A-24.8%$118.83MN/A-0.89N/AAnalyst Forecast
ALFIW
Alfi
0 of 5 stars
$0.00
flat
N/AN/A$0.00$200,684.000.00N/A
NLOK
NortonLifeLock
0 of 5 stars
$23.46
+15.3%
N/A+56.0%$13.40B$2.82B16.41N/AGap Up
High Trading Volume

Related Companies and Tools

This page (NASDAQ:CIDM) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners